Skip to content

CASCAID Study: Cytisine as a smoking cessation aid

A single-blind randomised controlled non-inferiority clinical trial to evaluate the efficacy and safety of cytisine compared to usual care (21mg, 14mg, or 7mg nicotine patch, 4mg or 2mg nicotine gum or 2mg or 1mg nicotine lozenge nicotine replacement therapy (NRT) plus behavioural support) as a treatment for people who wish to stop smoking

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12610000590066
Acronym
CASCAID
Enrollment
1310
Registered
2010-07-21
Start date
2011-03-29
Completion date
2013-02-04
Last updated
2021-11-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Cytisine is a medicine, derived from the Golden Rain Tree that partially blocks the effects of nicotine on the brain. Cytisine has been used as a smoking cessation treatment in several European countries since the 1960s, is inexpensive compared to other cessation medications and has few known side effects. Despite its long history of use there are few studies looking at whether cytisine actually works. Results from trials that have been undertaken suggest that taking cytisine almost doubles the chances of successfully quitting smoking, compared to a placebo. However, these studies were not conducted using modern research standards so their positive findings may not be valid. We propose to investigate the effectiveness of cytisine as a quit smoking aid and whether it is safe and acceptable to smokers.

Interventions

1. Tabex (Registered Trademark) oral tablet - 1.5 mg of cytisine per tablet (Sopharma) for 28 days. 2. Including 8 weeks of smoking cessation behavioural support supplied via Quitline New Zealand (NZ) (usually 3 telephone counselling calls over an 8 week period)

Sponsors

Health Research Council NZ
Lead SponsorGovernment body

Study design

Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Blinded (masking used)

Eligibility

Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. they want to stop smoking, 2. they are at least 18 years of age, 3. they are able to provide verbal consent, 4. they have access to a telephone.

Exclusion criteria

1. they are pregnant or breastfeeding, 2. they are current users of NRT products, 3. they are current users of non-NRT smoking cessation therapies (e.g. buproprion [Zyban], clonidine, nortriptyline, or varenicline [Champix]), 4. they are enrolled in another smoking cessation programme (e.g. Txt2Quit but concurrent referral to a face-to-face provider from Quitline is acceptable) or other cessation study (e.g. Fit2Quit), 5. they have had a heart attack, stroke, or severe angina within the previous two weeks, 6. they have uncontrolled high blood pressure (> 150 mmHg systolic, > 100 mmHg diastolic), 7. they have phaeochromocytoma, 8. they suffer from schizophrenia.

Outcome results

None listed

Source: ANZCTR · Data processed: Mar 27, 2026